ABBISKO-B (02256) climbed over 6%, reaching a new high of HK$18. As of press time, the stock was up 5.56% to HK$17.84, with turnover of HK$34.38 million.

On the news front, ABBISKO recently announced share repurchases of 200,000 shares on August 27 and another 100,000 shares on August 28. As of June 30, 2025, the company has cumulatively repurchased 9.545 million shares totaling HK$75.3 million.

Additionally, according to Hong Kong Stock Exchange filings, AllianzSE increased its holdings in ABBISKO on August 15, raising its stake from 4.81% to 5.10%.

Zhongtai Securities noted that the company achieved first-half revenue of 657 million yuan, up 20% year-over-year, and net profit of 328 million yuan, up 59% year-over-year. The company maintains strong cash reserves of 2.3 billion yuan, providing solid backing for future R&D and operations.

This growth was primarily driven by its core product pimasertib (ABSK021) through its partnership with Merck. In the first half of 2025, Merck exercised its global commercialization option for pimasertib and paid an $85 million option exercise fee.

Looking ahead, the company is positioned to benefit from milestone payments and sales royalties as pimasertib gains global approval and sales momentum. Given the company's steady progress in advancing pimasertib's registration and listing, its healthy financial performance appears sustainable in the medium term.